Your browser is no longer supported. Please, upgrade your browser.
MRTX Mirati Therapeutics, Inc. daily Stock Chart
MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.83 Insider Own0.40% Shs Outstand38.07M Perf Week0.37%
Market Cap4.03B Forward P/E- EPS next Y-5.50 Insider Trans-91.51% Shs Float37.58M Perf Month3.52%
Income-124.60M PEG- EPS next Q-1.21 Inst Own- Short Float14.31% Perf Quarter70.16%
Sales4.70M P/S857.71 EPS this Y-14.40% Inst Trans10.24% Short Ratio7.10 Perf Half Y69.51%
Book/sh8.11 P/B13.06 EPS next Y-11.30% ROA-47.40% Target Price110.42 Perf Year105.81%
Cash/sh7.91 P/C13.39 EPS next 5Y- ROE-52.10% 52W Range28.50 - 109.64 Perf YTD149.62%
Dividend- P/FCF- EPS past 5Y7.80% ROI- 52W High-3.42% Beta1.99
Dividend %- Quick Ratio12.20 Sales past 5Y- Gross Margin- 52W Low271.54% ATR3.79
Employees63 Current Ratio12.20 Sales Q/Q-87.40% Oper. Margin- RSI (14)62.05 Volatility3.12% 3.62%
OptionableYes Debt/Eq0.00 EPS Q/Q-129.30% Profit Margin- Rel Volume0.42 Prev Close103.30
ShortableYes LT Debt/Eq0.00 EarningsJul 31 BMO Payout- Avg Volume757.40K Price105.89
Recom2.10 SMA201.68% SMA5017.20% SMA20064.44% Volume321,825 Change2.51%
Jul-18-19Initiated Deutsche Bank Hold $86
Jun-19-19Downgrade B. Riley FBR Buy → Neutral $60 → $92
Jun-07-19Downgrade Guggenheim Buy → Neutral
Jun-05-19Reiterated H.C. Wainwright Buy $84 → $117
Jun-04-19Upgrade Citigroup Neutral → Buy $76 → $132
Apr-17-19Initiated JP Morgan Neutral $72
Mar-25-19Initiated Credit Suisse Outperform $85
Mar-04-19Downgrade Citigroup Buy → Neutral $64 → $77
Feb-15-19Initiated Piper Jaffray Overweight $85
Dec-03-18Initiated B. Riley FBR Buy $60
Oct-29-18Upgrade Guggenheim Neutral → Buy
Jul-09-18Reiterated Oppenheimer Outperform $35 → $62
Mar-12-18Initiated Barclays Overweight $44
Jan-09-18Reiterated H.C. Wainwright Buy $17 → $21
Nov-14-17Upgrade Leerink Partners Mkt Perform → Outperform
Oct-12-17Resumed H.C. Wainwright Buy $20
Sep-19-17Initiated Oppenheimer Outperform $18
Sep-15-17Reiterated Leerink Partners Mkt Perform $7 → $9
Nov-17-16Initiated H.C. Wainwright Buy $12
Jun-06-16Reiterated Wedbush Outperform $29 → $27
Jul-18-19 07:35AM  Is Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Pay Fair? Simply Wall St.
Jul-10-19 05:53PM  Mirati Inks Deal with Novartis to Evaluate Tumor Candidate Zacks
04:41PM  How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug Investor's Business Daily
07:17AM  The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV Benzinga
Jul-09-19 04:30PM  Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155 PR Newswire
Jul-02-19 07:29AM  The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug Benzinga
Jul-01-19 04:30PM  Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors PR Newswire
Jun-30-19 08:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jun-27-19 04:05PM  Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Jun-25-19 08:30AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jun-24-19 04:01PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
09:43AM  Read This Before You Buy Any New Cancer Drug Stocks Motley Fool
Jun-18-19 07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-14-19 08:41AM  Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options Zacks
Jun-13-19 11:51AM  3 Under-the-Radar Stocks Trading at All-Time Highs Investopedia
Jun-12-19 10:03AM  Mirati Therapeutics, Inc. (NASDAQ:MRTX): Financial Strength Analysis Simply Wall St.
Jun-10-19 10:26AM  Hedge Funds Have Never Been This Bullish On Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Jun-06-19 03:12PM  Mirati Therapeutics Could Soar Even Higher TheStreet.com
Jun-05-19 07:30AM  The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache Benzinga
Jun-04-19 03:18PM  The 10 Best Stocks for 2019 So Far InvestorPlace +9.90%
12:37PM  Amgens Good News on Lung Cancer Boosted Mirati Therapeutics. Heres What Wall Street Is Saying. Barrons.com
10:53AM  How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's? Benzinga
10:19AM  Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity Zacks
09:21AM  3 Cancer Stocks Given a Lift by Amgen Motley Fool
Jun-03-19 02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks +31.58%
12:47PM  Amgen Stock Jumps on Promising Cancer Drug Trial Results Barrons.com
12:18PM  Here's Why Mirati Therapeutics Is Jumping Today Motley Fool
May-31-19 01:04PM  What to watch at the world's largest cancer conference CNBC Videos
May-30-19 04:30PM  Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference PR Newswire
May-16-19 04:14PM  Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting Investor's Business Daily +11.13%
02:47PM  Here's Why Mirati Therapeutics Is Surging Today Motley Fool
10:47AM  What's Triggering The Rise In Mirati Shares? Benzinga
May-14-19 08:42AM  Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock Zacks
May-07-19 07:10AM  What You Must Know About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) Beta Value Simply Wall St.
Apr-29-19 05:10PM  Mirati: 1Q Earnings Snapshot Associated Press
04:05PM  Mirati Therapeutics Reports First Quarter 2019 Financial Results PR Newswire
02:52PM  Were Hedge Funds Right About Flocking Into Mirati Therapeutics, Inc. (MRTX) ? Insider Monkey
Apr-01-19 04:30PM  Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference PR Newswire
Mar-26-19 12:21PM  The Mirati Therapeutics (NASDAQ:MRTX) Share Price Has Gained 287%, So Why Not Pay It Some Attention? Simply Wall St.
Mar-05-19 04:30PM  Mirati Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
Feb-28-19 04:15PM  Mirati Therapeutics Reports Fourth Quarter Financial Results PR Newswire -5.02%
Feb-25-19 08:10AM  Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-19-19 04:15PM  Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors PR Newswire
Feb-07-19 04:30PM  Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day PR Newswire
Feb-04-19 05:01PM  Here's Why Mirati Therapeutics Jumped 55.8% in January Motley Fool
Jan-31-19 07:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics ACCESSWIRE
Jan-30-19 11:41AM  How Many Insiders Sold Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares? Simply Wall St. +5.31%
Jan-23-19 07:22AM  The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga
Jan-22-19 04:01PM  Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Jan-17-19 08:06AM  The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US Benzinga
Jan-16-19 08:45PM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
04:01PM  Mirati Therapeutics Announces Proposed Public Offering Of Common Stock PR Newswire
Jan-15-19 04:21PM  Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor PR Newswire
07:55AM  Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics ACCESSWIRE
Jan-10-19 06:00AM  Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause ACCESSWIRE +13.27%
Jan-09-19 08:39AM  Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4% Zacks +5.46%
Jan-07-19 08:30AM  Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®) PR Newswire +7.31%
Jan-02-19 04:30PM  Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference PR Newswire +5.26%
Dec-20-18 04:42PM  Mirati Therapeutics Added To NASDAQ Biotechnology Index PR Newswire
Dec-12-18 03:27AM  Hedge Funds Are Buying Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Dec-10-18 04:15PM  Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors PR Newswire
Dec-04-18 07:20AM  Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar Discovering Underlying Factors of Influence GlobeNewswire
Nov-30-18 08:25AM  The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings Benzinga
Nov-29-18 05:20PM  Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849 PR Newswire -5.56%
Nov-20-18 04:30PM  Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-09-18 08:35AM  Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting PR Newswire -5.65%
08:30AM  Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting PR Newswire
Nov-08-18 04:32PM  Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors PR Newswire
Nov-07-18 09:00AM  Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference PR Newswire +6.95%
Nov-06-18 06:52PM  Mirati: 3Q Earnings Snapshot Associated Press
04:15PM  Mirati Therapeutics Reports Third Quarter Financial Results PR Newswire
Nov-05-18 04:15PM  Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting PR Newswire
Oct-30-18 09:00AM  Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer PR Newswire +6.11%
Oct-25-18 08:50AM  Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +5.50%
Oct-22-18 04:49PM  Mirati Shares Fall After Cancer Trial Progress Report TheStreet.com -15.00%
04:45PM  Biotech Dives After Lung Cancer Regimen With Bristol Disappoints Investor's Business Daily
04:26PM  These Companies Are Dragging Biotech Stocks Into A Pit On Cancer Tests Investor's Business Daily
11:51AM  Why Mirati Therapeutics Inc. Is Plunging Today Motley Fool
10:37AM  Mirati Therapeutics stock drops 19.5% after cancer trial results MarketWatch
06:10AM  Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial PR Newswire
Oct-21-18 05:10AM  Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress PR Newswire
Oct-15-18 04:30PM  Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call PR Newswire
Oct-09-18 09:41AM  3 Biotech Stocks With Major Incoming Catalysts Motley Fool
Oct-08-18 05:29PM  Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy Zacks
Sep-14-18 11:15AM  Mirati Therapeutics Inc (NASDAQ:MRTX): Time For A Financial Health Check Simply Wall St.
Aug-29-18 04:30PM  Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference PR Newswire
Aug-24-18 07:11AM  Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar? Zacks
Aug-16-18 04:30PM  Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition PR Newswire
Aug-01-18 06:53PM  Mirati: 2Q Earnings Snapshot Associated Press
04:15PM  Mirati Therapeutics Reports Second Quarter Financial Results PR Newswire
09:15AM  Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar? Zacks
Jul-28-18 08:00AM  How to Invest in Clinical-Stage Biotechs Without Losing Money Motley Fool
Jul-24-18 04:59PM  Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress PR Newswire
Jul-17-18 07:35AM  Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks ACCESSWIRE +5.11%
Jun-25-18 04:30PM  Mirati Therapeutics Added to Russell 2000® Index PR Newswire
Jun-15-18 09:20AM  Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar? Zacks
Jun-11-18 04:15PM  Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jun-07-18 11:26AM  Here's Why Mirati Therapeutics, Inc. Is Rising Today Motley Fool +18.40%
08:00AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jun-06-18 04:01PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a Clinical Collaboration Agreement with Novartis International AG. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARTER BRUCE L ADirectorMay 22Option Exercise6.783,00020,3403,000May 24 05:00 PM
CARTER BRUCE L ADirectorMay 22Sale75.203,000225,5970May 24 05:00 PM
Donadio Jamie ASr. VP, CFOMay 16Option Exercise5.507,50041,2507,721May 20 07:00 PM
Donadio Jamie ASr. VP, CFOMay 16Sale75.007,500562,500221May 20 07:00 PM
GREY MICHAEL GDirectorMay 13Option Exercise16.847,100119,5647,100May 15 07:00 PM
GREY MICHAEL GDirectorMay 13Sale65.305,760376,1381,340May 15 07:00 PM
venBio Select Advisor LLC10% OwnerMar 20Sale72.8023,7811,731,2573,862,500Mar 20 04:05 PM
venBio Select Advisor LLC10% OwnerMar 19Sale73.43100,0007,343,0003,886,281Mar 20 04:05 PM
venBio Select Advisor LLC10% OwnerMar 18Sale76.55125,0009,568,7503,986,281Mar 20 04:05 PM
Boxer Capital, LLC10% OwnerMar 01Option Exercise0.00425,0064251,715,566Mar 05 09:30 PM
Braslyn Ltd.10% OwnerMar 01Option Exercise0.00275,0042753,135,970Mar 05 09:30 PM
Boxer Capital, LLC10% OwnerMar 01Sale69.00425,00029,325,0001,290,560Mar 05 09:30 PM
Braslyn Ltd.10% OwnerMar 01Sale69.00275,00018,975,0002,860,966Mar 05 09:30 PM
BAUM CHARLES MPresident & CEOFeb 25Option Exercise8.5051,810440,385117,851Feb 27 07:00 PM
BAUM CHARLES MPresident & CEOFeb 25Sale75.6751,8103,920,67266,041Feb 27 07:00 PM
BAUM CHARLES MPresident & CEOFeb 21Option Exercise21.583,62378,17366,041Feb 25 08:04 PM
CARTER BRUCE L ADirectorFeb 20Option Exercise6.783,00020,3403,000Feb 22 07:00 PM
venBio Select Advisor LLC10% OwnerFeb 20Sale73.00686,82050,137,8604,111,281Feb 21 04:10 PM
CARTER BRUCE L ADirectorFeb 20Sale73.643,000220,9210Feb 22 07:00 PM
Donadio Jamie ASr. VP, CFOFeb 15Option Exercise5.407,50040,5007,721Feb 19 07:00 PM
Donadio Jamie ASr. VP, CFOFeb 15Sale75.007,500562,502221Feb 19 07:00 PM
LEMASTERS CHRISTOPHER C.EVP, Chief Business OfficerFeb 14Option Exercise6.4560,000387,00060,000Feb 19 07:00 PM
LEMASTERS CHRISTOPHER C.EVP, Chief Business OfficerFeb 14Sale71.7760,0004,306,4550Feb 19 07:00 PM
Johnson Craig ADirectorJan 29Option Exercise8.6517,000147,03017,000Jan 31 07:00 PM
Johnson Craig ADirectorJan 29Sale61.4617,0001,044,7730Jan 31 07:00 PM
CHEN ISANEVP, Chief Medical OfficerJan 23Option Exercise22.4787019,54735,836Jan 25 07:00 PM
Boxer Capital, LLC10% OwnerJan 17Buy62.00150,0009,300,0001,715,560Jan 22 05:34 PM
Reisman Neil10% OwnerJan 11Option Exercise12.8925,972334,68739,103Jan 15 09:15 PM
Boxer Capital, LLC10% OwnerJan 09Option Exercise0.00150,0031501,565,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 09Sale51.55150,0007,732,1001,415,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 08Option Exercise0.00550,0125501,565,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 08Sale52.10550,00028,657,0721,015,560Jan 09 09:31 PM
Davis Aaron I.DirectorJan 08Sale52.8010,000528,00037,052Jan 09 09:31 PM
Davis Aaron I.DirectorJan 07Sale46.4040,0001,855,80347,052Jan 09 09:31 PM
Christensen JamieEVP, Chief Scientific OfficerDec 26Option Exercise17.415,16989,9928,789Dec 28 07:00 PM
BAUM CHARLES MPresident & CEOAug 24Option Exercise17.4111,486199,97162,418Aug 24 07:00 PM
BAUM CHARLES MPresident & CEOAug 23Option Exercise8.5051,810440,385102,742Aug 24 07:00 PM
BAUM CHARLES MPresident & CEOAug 23Sale57.5551,8102,981,78850,932Aug 24 07:00 PM